ZZZ3 Inhibitors
Chemical inhibitors of the ZZZ3 protein function by influencing various signaling pathways and protein interactions that are essential for its activity within protein complexes. Spautin-1 promotes the degradation of components in the PI3K/Akt pathway, which is crucial for ZZZ3 function, by inhibiting the action of USP10 and USP13, enzymes responsible for removing ubiquitin from proteins and preventing their degradation. Similarly, LY294002 and Wortmannin directly inhibit PI3K, leading to reduced Akt activity. Since ZZZ3 is regulated by the Akt signaling pathway, these inhibitors can suppress the activation of ZZZ3 within its protein complexes. Triciribine takes a more targeted approach by specifically inhibiting the activation of Akt itself, thereby directly diminishing ZZZ3's functional activity.
Furthermore, Rapamycin indirectly affects ZZZ3 by inhibiting mTOR, a protein that interacts with ZZZ3-associated complexes, thus influencing ZZZ3's regulatory function. U0126 and PD98059 are inhibitors of MEK, a kinase within the MAPK/ERK pathway, and by inhibiting MEK, these compounds prevent the activation of ERK, another kinase that can regulate ZZZ3 activity. SB203580 targets p38 MAP kinase within the MAPK pathway, which also has implications for ZZZ3's function. Additionally, LFM-A13 disrupts the signaling pathways associated with ZZZ3 by inhibiting Bruton's tyrosine kinase (BTK). C646, by inhibiting p300, a histone acetyltransferase, can affect chromatin structure and gene expression, processes in which ZZZ3 is implicated due to its involvement in chromatin remodeling complexes. Quercetin, a flavonoid, inhibits PI3K among other kinases and consequently can suppress ZZZ3's activity. Lastly, Sunitinib, a tyrosine kinase inhibitor, can disrupt multiple receptor tyrosine kinases involved in signaling pathways that regulate the functional involvement of ZZZ3 within its complexes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 is known to promote the degradation of PI3K/Akt pathway components through inhibition of USP10 and USP13, deubiquitinating enzymes. Since ZZZ3 is involved in the PI3K/Akt pathway through its association with regulatory complexes, the degradation of pathway components can lead to the functional inhibition of ZZZ3. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is upstream of the Akt signaling pathway. ZZZ3 functions as part of a protein complex that is regulated by Akt signaling. Inhibition of PI3K can suppress Akt activation, which in turn can inhibit the regulatory effects of ZZZ3 within its protein complex. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can suppress PI3K-dependent Akt phosphorylation. As ZZZ3 activity is regulated by Akt signaling, downregulating this pathway can inhibit the functional activity of ZZZ3 in its associated protein complexes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in a pathway that is known to interact with the ZZZ3-associated protein complexes. By inhibiting mTOR, Rapamycin can inhibit downstream signals that regulate ZZZ3 function within these complexes. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the activation of Akt, a kinase that modulates the function of ZZZ3 through its downstream signaling. By inhibiting Akt, Triciribine can lead to the functional inhibition of ZZZ3 in its role within the protein complex. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway. ZZZ3 is regulated by the MAPK/ERK pathway, and inhibition of MEK by U0126 can prevent the phosphorylation and activation of ERK, thereby inhibiting the functional influence of ZZZ3 within its complex. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor that prevents the activation of MAPK/ERK kinase. By inhibiting this kinase, PD98059 can suppress the MAPK/ERK pathway and thus inhibit ZZZ3's functional role in the pathway's associated protein complexes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is part of the MAPK pathway. ZZZ3 has been linked to the MAPK pathway through its protein complex associations. Inhibition of p38 MAP kinase can lead to the functional inhibition of ZZZ3's role within these complexes. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
LFM-A13 is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is related to the regulation of various signaling pathways, including those associated with ZZZ3. Inhibiting BTK can lead to disruption of these pathways, potentially inhibiting the functional role of ZZZ3. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a selective inhibitor of p300, a histone acetyltransferase that can modulate chromatin structure and gene expression. As ZZZ3 is involved in chromatin remodeling complexes, inhibition of p300 can disrupt the function of these complexes, thereby inhibiting ZZZ3. | ||||||